 |
27 Products |  |
14 Diseases | | 27 Products |
|
13 Trials |  |
837 News |  |
| «123456789» |
- || zenuzolac (VGX-1027) / GeneOne
Trial initiation date: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - Feb 3, 2021
P2, N=132, Not yet recruiting, Sponsor: GeneOne Life Science, Inc.
Initiation date: Nov 2020 --> Feb 2021
- || INO-4800 / Inovio, The Wistar Institute
U owe #INO & it’s honorable & dedicated scientist an APOLOGY for slandering there reputation! Prove U have changed & write the truth about this Honorable company! @AOC @SenWarren @CDCDirector @DrWoodcockFDA @VP people r dying & #INO4800 is the answer! #Dr.Fauci knows the truth (Twitter) - Feb 2, 2021
- | INO-4800 / Inovio, The Wistar Institute
@InovioPharma INO 4800 a better solution. (Twitter) - Jan 31, 2021
- || INO-4800 / Inovio, The Wistar Institute
Trial completion date, Trial primary completion date: Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers (clinicaltrials.gov) - Jan 22, 2021
P1, N=120, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Initiation date: Nov 2020 --> Feb 2021 Trial completion date: Jul 2021 --> Jan 2022 | Trial primary completion date: Jul 2021 --> Jan 2022
- ||| INO-4800 / Inovio, The Wistar Institute
Please see what you can do to help expedite Inovio Pharmaceuticals CoVid vaccine INO-4800. It's ultra safe, highly effective, can be boosted and requires no cold chain. (Twitter) - Jan 21, 2021
- ||| INO-4800 / Inovio, The Wistar Institute
Clinical, P1 data: It’s so disappointing. With Hilda I asked if she promised to provide commentary on phase 1 prior to it being released. Then I was blocked for asking questions about safety of vaccines. Her only tweet about ino-4800 ph1 may as well have been a nothing burger. (Twitter) - Jan 20, 2021
- || INO-4800 / Inovio, The Wistar Institute
I’ve been blocked now by @EricTopol @hildabast about commenting on ino-4800 next is @PeterHotez and @DrEricDing I guess. Although I do like their commentary. (Twitter) - Jan 20, 2021
- ||| INO-4800 / Inovio, The Wistar Institute
This vaccine has CD8+ data included -- are you saying this might suggest ADE? it's INO-4800 fro, INOVIO btw (Twitter) - Jan 19, 2021
- ||||| INO-4800 / Inovio, The Wistar Institute
Clinical, Review: A follow up of INO-4800 AE profile from Peer Review. It also elicited 100% immune response with respectable NAB and T-cells. absolutely no comparison between mRNA and dna plasmid with cellectra with regards to tolerability and safety.. none #covid19 #vaccine $ino (Twitter) - Jan 15, 2021
- || INO-4800 / Inovio, The Wistar Institute
Repeat after me 3 times Inovio - INO-4800 (Twitter) - Jan 9, 2021
- ||| INO-4800 / Inovio, The Wistar Institute
🧬Did you here about the 3rd one being held back. It’s not a secret. INO-4800. Learn more @INOVIO.com🧬 (Twitter) - Jan 8, 2021
- || INO-4800 / Inovio, The Wistar Institute
Clinical, P1 data, Journal: Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. (Pubmed Central) - Jan 5, 2021
P1
INO-4800 demonstrated excellent safety and tolerability and was immunogenic in 100% (38/38) of the vaccinated subjects by eliciting either or both humoral or cellular immune responses. Coalition for Epidemic Preparedness Innovations (CEPI).
- || INO-4800 / Inovio, The Wistar Institute
#INO4800 P2 is alrdy underway in China based on promising data from US & Chinese P1 trials. The latter started in Aug. while the US P1 started in April & completed in June. Why @InovioPharma's P2 has been held back for so long? @US_FDA favoring BPs? @EricTopol @DrEricDing (Twitter) - Jan 4, 2021
- [VIRTUAL] Molecular insight of SARS-CoV-2: viral structure, infection mechanism, antiviral agents, and vaccine development () - Dec 26, 2020 - Abstract #ASHP2020ASHP_2846;
Currently, companies in late-phase trials such as Moderna, Pfizer, AstraZeneca, Inovio, Johnson and Johnson, and Novavax are on their way to developing a successful vaccine. As for an antiviral drug, Remdesivir is available through the FDA Emergency Use Authorization that has shown to benefit hospitalized individuals with severe SARS-CoV-2 for a 5- or 10-day therapy regimen.
- ||||| INO-4800 / Inovio, The Wistar Institute
P1 data, Review: The potential for high rate of Adverse reactions has always been a known based on phase 1 data from all the vaccine candidates. So far moderna and Pfizer have rung true. Especially the second dose. We are waiting for peer review data of ino-4800 to be published (Twitter) - Dec 22, 2020
- ||| INO-4800 / Inovio, The Wistar Institute
Would be nice if @SteveFDA & @CDCDirector can be trusted but so far, they have NOT been transparent with the American public! Operation “Select Speed” has held @InovioPharma #INO4800 back when they are the most transparent & safest #Covid_19 data to date! The truth will come out! (Twitter) - Dec 20, 2020
- ||| INO-4800 / Inovio, The Wistar Institute
Clinical: I really don’t think a pragmatic epidemiologist is going to prefer one over the other given the severity of the situation. That’s not take away from INO-4800 as we will need a half dozen or more vaccines. (Twitter) - Dec 13, 2020
- || PENNVAX-GP (HIV DNA vaccine) / Inovio
Clinical, Journal: Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults. (Pubmed Central) - Dec 12, 2020
As for an antiviral drug, Remdesivir is available through the FDA Emergency Use Authorization that has shown to benefit hospitalized individuals with severe SARS-CoV-2 for a 5- or 10-day therapy regimen. ID/EP and IM/EP are distinct experiences; however, HIV-1 DNA vaccination by either route was safe, tolerable and acceptable by most study participants.
- ||| GNOS-PV02 / Geneos Therap
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: GT-30: GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC (clinicaltrials.gov) - Dec 8, 2020
P1/2, N=24, Recruiting, Sponsor: Geneos Therapeutics
ID/EP and IM/EP are distinct experiences; however, HIV-1 DNA vaccination by either route was safe, tolerable and acceptable by most study participants. N=12 --> 24 | Trial completion date: Jul 2021 --> Feb 2022 | Trial primary completion date: May 2021 --> Dec 2021
- || INO-4800 / Inovio, The Wistar Institute
ارتفاع $INO بعد اعلان شراكه جديدة مع شركة Kaneka Eurogentec S.A! لتصنيع لقاح INO-4800 المخصص لمعالجة فيروس كرورنا ! هذه تعتبر الشراكة الثانية بعد Thermo Fisher قبل شهرين تقريباً! @thermofisher @InovioPharma (Twitter) - Dec 3, 2020
- || INO-4800 / Inovio, The Wistar Institute
Adverse events: @InovioPharma #DNAMedicine #DNAVaccine @ThermoFisherPR @JoeBiden @DrBiden #INO4800 No call chain problems, no side effects. @OlogyBio (Twitter) - Dec 3, 2020
- | INO-4800 / Inovio, The Wistar Institute
.. @thermofisher plans 100 million doses of #INO4800 annually. (Twitter) - Dec 3, 2020
- |||||| INO-4800 / Inovio, The Wistar Institute
Enrollment open: INNOVATE: Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure (clinicaltrials.gov) - Dec 3, 2020
P2/3, N=6578, Recruiting, Sponsor: Inovio Pharmaceuticals
N=12 --> 24 | Trial completion date: Jul 2021 --> Feb 2022 | Trial primary completion date: May 2021 --> Dec 2021 Not yet recruiting --> Recruiting
- | MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Metastases: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers (clinicaltrials.gov) - Dec 2, 2020
P2, N=77, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Jan 2020 --> Dec 2022 | Trial primary completion date: Jan 2020 --> Dec 2021
- |||||||||| INO-4800 / Inovio, The Wistar Institute
New P2/3 trial: INNOVATE: Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure (clinicaltrials.gov) - Nov 24, 2020
P2/3, N=6578, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- |||| INO-4800 / Inovio, The Wistar Institute
Adverse events: @PeterHotez INO4800 is the ONLY vaccine with no deep freezing needed, 1 yr room temperature durability and no adverse side effects ONLY redness on injection site. Please help Inovio save lives (Twitter) - Nov 24, 2020
- ||| INO-5401 / Inovio
BRCA Biomarker: INO 5401 Vaccination in BRCA1/2 Mutation Carriers #inovio $ino (Twitter) - Nov 19, 2020
- |||| INO-4800 / Inovio, The Wistar Institute
Adverse events: @CDCDirector How can operation warp speed give a major bump for Moderna and NOVAVAX that need refrigeration and deep freezing whereas INO4800 from Inovio HAS 1 year lasting in room temperature with no adverse side effects. A shame! #actnow #savelives (Twitter) - Nov 18, 2020
- | INO-4800 / Inovio, The Wistar Institute
$INO INO-4800 a top-10 vaccine candidate - Benchmark. Maintains Buy, PT $25 (Twitter) - Nov 17, 2020
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Trial completion date, Trial primary completion date, Combination therapy: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov) - Nov 16, 2020
P1/2, N=52, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Jan 2020 --> Dec 2022 | Trial primary completion date: Jan 2020 --> Dec 2021 Trial completion date: Jan 2021 --> Jun 2021 | Trial primary completion date: Jan 2021 --> Jun 2021
- ||| INO-4500 / Inovio
Trial completion: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers (clinicaltrials.gov) - Nov 16, 2020
P1, N=60, Completed, Sponsor: Inovio Pharmaceuticals
Trial completion date: Jan 2021 --> Jun 2021 | Trial primary completion date: Jan 2021 --> Jun 2021 Active, not recruiting --> Completed
- |||| INO-4800 / Inovio, The Wistar Institute
Clinical: That's not enough! Need vaccine w/ near 100% & lasting efficacy! #INO-4800 #Inovio @drsanjaygupta @US_FDA @CDCDirector @CDCgov BioNTech scientist: Vaccine could halve virus transmission https://t.co/va68ptU4oe (Twitter) - Nov 15, 2020
- | bizalimogene ralaplasmid (VGX-3100) / Inovio
Trial primary completion date: VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 (clinicaltrials.gov) - Nov 13, 2020
P2, N=22, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: May 2021 --> Jun 2020
- |||| #Inovio $INO #INO4800 #INO5401 #GBM data on the 19th #VIN #AIN data #ZIKA data #SNO2020 #VGX3100 (Twitter) - Nov 4, 2020
- ||| #Inovio $INO #INO4800 #INO5401 #GBM data on the 19th #VIN #AIN data #ZIKA data #SNO2020 #VGX3100 $REGN (Twitter) - Nov 2, 2020
- |||| INO-4800 / Inovio, The Wistar Institute
Clinical: INO 4800 is the way to go!!!!!!! Yrs of vaccine data on safety and efficacy related to coronavirus (MERS/Covid) (Twitter) - Oct 31, 2020
- Libtayo (cemiplimab) / Sanofi, Regeneron, INO-9012 / Inovio, INO-5401 / Inovio
[VIRTUAL] INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma () - Oct 24, 2020 - Abstract #SNO2020SNO_268;
P1/2
Overall survival is encouraging. Clinical trial information: NCT03491683.
- | INO-4800 / Inovio, The Wistar Institute
Journal: Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein. (Pubmed Central) - Oct 23, 2020
Through this approach, supported by biomolecular modelling of this mutation and the commonly-associated P314L mutation in the RNA-dependent RNA polymerase, we have shown that there is no experimental evidence to support this speculation. We additionally demonstrate that the putative elastase cleavage site introduced by the D614G mutation is unlikely to be accessible to proteases.
- || INO-4800 / Inovio, The Wistar Institute
Sir @InovioPharma #INO4800 (Twitter) - Oct 22, 2020
- ||||| INO-4700 / GeneOne, Inovio
New P2 trial: Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers (clinicaltrials.gov) - Oct 19, 2020
P2, N=542, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- |||| zenuzolac (VGX-1027) / GeneOne
New P2 trial: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - Oct 18, 2020
P2, N=132, Not yet recruiting, Sponsor: GeneOne Life Science, Inc.
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment change, Trial initiation date, Trial primary completion date, Combination therapy, BRCA Biomarker: INO 5401 Vaccination in BRCA1/2 Mutation Carriers (clinicaltrials.gov) - Oct 14, 2020
P1b, N=44, Not yet recruiting, Sponsor: University of Pennsylvania
We additionally demonstrate that the putative elastase cleavage site introduced by the D614G mutation is unlikely to be accessible to proteases. N=28 --> 44 | Initiation date: Sep 2020 --> Dec 2020 | Trial primary completion date: Sep 2020 --> Dec 2025
- || INO-4800 / Inovio, The Wistar Institute
Ffs! @InovioPharma hasn’t published data to allow anyone to claim they generate any sort of immune response to INO-4800 never mind a ‘balanced’ one. Please get off the pony and start lobbying them to pull their finger out rather than slating others (Twitter) - Oct 14, 2020
- || INO-6145 / Inovio, PENNVAX-GP (HIV DNA vaccine) / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Trial completion date, Trial primary completion date: Therapeutic Vaccination in Treated HIV Disease (clinicaltrials.gov) - Oct 12, 2020
P1/2, N=60, Recruiting, Sponsor: Steven Deeks
N=28 --> 44 | Initiation date: Sep 2020 --> Dec 2020 | Trial primary completion date: Sep 2020 --> Dec 2025 Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- ||| INO-4800 / Inovio, The Wistar Institute
Clinical: Your least favorite #Inovio has the answer. #DNAMedicine #INO4800 A partial clinical hold due to the device sure beats $JNJ ‘s, Unexplained illness hold. $INO #BecauseTheWorldCantWait. (Twitter) - Oct 12, 2020
- ||| INO-4800 / Inovio, The Wistar Institute
#INO4800 found equally effective against COVID-19 D & G strains by Australian researchers! @CEPIvaccines @gatesfoundation @US_FDA @SteveFDA @CDCgov @CDCDirector @InovioPharma @WHO @inoviolt (Twitter) - Oct 8, 2020
- ||| MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Very insightful presentation. Could you please tell more about the future plan for MEDI0457 durva combo in HPV+ SCCHN or Cervical? . Any pivotal trial initiation like Biontech ? (Twitter) - Sep 20, 2020
- ||| INO-4800 / Inovio, The Wistar Institute
Inovio INO-4800 (Twitter) - Sep 20, 2020
- ||||| MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Clinical: Safety and efficacy of MEDI0457, a DNA immunotherapeutic vaccine expressing HPV 16/18 E6/E7 proteins and IL-12 plus durvalumab in pts w HPV+ r/m HNSCC. ORR=22%. Surprisingly modest? @CharuAggarwalMD https://t.co/glGWWgVKOt (Twitter) - Sep 20, 2020